Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Thenorth1990on Aug 10, 2021 4:04pm
110 Views
Post# 33679703

RE:RE:RE:RE:RE:For those that Sold at 0.26 CAD Today

RE:RE:RE:RE:RE:For those that Sold at 0.26 CAD TodayWe are due for some PR since sometime. Last one was for the appointment for commercialization of serology test. All pp are not nessecary bad, how else are we gonna keep finding cash to fund these research unless we have revenue from serology. Last one was pp for convertible debentures, which gave us new life. They filed short term prospectus on March 5th and funding announcement by end of march. Not sure how it will play out this time . Also I guess it is safe to assume that , any further funding will be from Boston group as they risked lending us before biogen . Also There was a previous ppt they specifically talked about funding assurance from bankers after biogen approval. But now I can't find it ..
<< Previous
Bullboard Posts
Next >>